Men: Benefit and Harms of PSA Screening for Prostate Cancer
The United States Preventive Services Task Force (USPSTF) has analyzed the data from the PLCO, ERSPC, and other trials. It is estimated that for every 1,000 men ages 55 to 69 years who are screened every 1 to 4 years for a decade*.
*: Moyer VA on behalf of the U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Annals of Internal Medicine 2012; 157(2):120–134
- The PSA test measures the blood level of PSA, a protein that is produced by the prostate gland. The higher a man’s PSA level, the more likely it is that he has prostate cancer. However, there are additional reasons for having an elevated PSA level, and some men who have prostate cancer do not have elevated PSA.
- The PSA test has been widely used to screen men for prostate cancer. It is also used to monitor men who have been diagnosed with prostate cancer to see if their cancer has recurred (come back) after initial treatment or is responding to therapy.
- Some advisory groups now recommend against the use of the PSA test to screen for prostate cancer because the benefits, if any, are small and the harms can be substantial. None recommend its use without a detailed discussion of the pros and cons of using the test.
An infographic illustrating the benefit and harms of PSA screening for prostate cancer.